Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

May 31, 2024Open Access

Ver artículo completo

Antibody design enters the AI era

BDBiopharma DealmakersWWF Colombia

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Major biopharma companies are setting up partnerships with companies that are pioneering the application of artificial intelligence tools to develop therapeutic antibodies. Major biopharma companies are setting up partnerships with companies that are pioneering the application of artificial intelligence tools to develop therapeutic antibodies.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Biopharma Dealmakers (Fri,) studied this question.

synapsesocial.com/papers/68e67624b6db6435876006ca https://doi.org/https://doi.org/10.1038/d43747-024-00030-w

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Antibody design enters the AI era | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Applying artificial intelligence to accelerate and de-risk antibody discovery2024 · 10 citations
2AI-accelerated therapeutic antibody development: practical insights

2024 · 10 citations

3Artificial intelligence-driven computational methods for antibody design and optimization2025 · 21 citations

4Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development2025 · 20 citations

5Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering2026